---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-034095"
form_type: "8-K"
ticker: "CRVO"
cik: "0001053691"
company_name: "CervoMed Inc."
filed_at: "2025-11-10T23:59:59+00:00"
generated_at: "2026-05-16T22:12:37.450305+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# CervoMed reports Q3 2025 net loss $7.7M; FDA aligned on Phase 3 trial design for neflamapimod in DLB

## Summary
- Net loss of $7.7M for Q3 2025 vs $4.8M in Q3 2024; cash $27.3M at Sept 30, 2025.
- FDA alignment on design of planned Phase 3 trial of neflamapimod for dementia with Lewy bodies; global pivotal trial initiation targeted H2 2026.
- Phase 2b RewinD-LB 32-week data showed 64% risk reduction in clinically significant worsening on CDR-SB (p<0.001) in DLB patients with low AD co-pathology.
- R&D expenses $6.0M (up $0.9M YoY) primarily due to increased personnel and CMC activities; G&A $2.3M.

## SEC filing metadata
- accession: 0001437749-25-034095
- form_type: 8-K
- ticker: CRVO
- cik: 0001053691
- company_name: CervoMed Inc.
- filed_at: 2025-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1053691/000143774925034095/0001437749-25-034095-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1053691/000143774925034095/crvo20251110_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-034095
- JSON: https://secwatch.observer/filing/0001437749-25-034095.json
- Plain text: https://secwatch.observer/filing/0001437749-25-034095.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.